Thermo Fisher Scientific (TMO) is back in focus after a string of biopharma updates, including a new role running Quantum BioPharma’s Phase 2 Lucid MS trial for progressive multiple sclerosis.
Those contract wins and product launches are arriving against a backdrop of strong momentum in Thermo Fisher Scientific’s stock, with a 90-day share price return of 26.18% and a 1-year total shareholder return of 23.91%. This comes even though the 7-day share price return has eased 1.92% following a recent 30-day share price gain of 7.87%.
Scan how Thermo Fisher Scientific’s contract wins and trial work compare with peers by reviewing our curated list of 34 healthcare AI stocks in similar AI and biopharma workflows.
Thermo Fisher Scientific now trades only slightly below the average analyst target after a powerful 3 month run. Is that small discount a signal of lingering market caution, or a fair cap on near term optimism before valuation work starts to bite?
Most Popular Narrative: 1% Overvalued
Thermo Fisher Scientific’s most followed valuation storyline pegs fair value at $652.85, a touch below the $662.06 last close. This leaves the stock almost exactly aligned with that long term model while still pricing in steady execution on its pharma focused plan.
Improving funding and higher activity in pharma and biotech, which represent about 60% of Thermo Fisher Scientific revenue and have delivered several quarters of sequentially stronger organic growth, are expected to support continued demand for research reagents, clinical trial services and bioproduction, with a direct effect on revenue growth and operating leverage.
See why 93 investors see Thermo Fisher Scientific as 1% overvalued.
Result: Fair Value of $652.85 (OVERVALUED)
Still, the Thermo Fisher Scientific story can be knocked off course if pharma funding softens again or if the microbiology divestiture drags more on earnings than expected.
Find out about the key risks to this Thermo Fisher Scientific narrative.
Another View on Thermo Fisher Scientific’s Valuation
On simple earnings multiples, Thermo Fisher Scientific looks more forgiving than it first appears. The stock trades on a P/E of 34.8x, below both the global Life Sciences group at 38.4x and its peer average of 38.1x, yet slightly above a fair ratio of 33.7x that the market could move toward. That mix of small premium to fair ratio but discount to sector and peers raises a practical question for investors: Is this pricing a modest cushion or a sign that expectations are already tight if sentiment cools?
To see how that earnings multiple stacks up in more detail, including the gap to the fair ratio and how other companies are priced, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on Thermo Fisher Scientific so far. If you want your own verdict, move quickly, review the full picture, and weigh up 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Thermo Fisher Scientific?
If Thermo Fisher Scientific has your attention, do not stop there. Put a few more high quality ideas on your radar before the next market move.
- Target resilient compounding potential by scanning companies in our 27 high quality undervalued stocks that combine solid fundamentals with pricing that still looks reasonable.
- Prioritize capital strength and fewer balance sheet surprises through the list of solid balance sheet and fundamentals (25 results), so you can focus on the thesis instead of short term stress.
- Hunt for under the radar opportunities using the 19 high quality undiscovered gems and avoid missing stocks that have quality metrics but limited current attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com